XHKG2142
Market cap140mUSD
Dec 23, Last price
1.42HKD
1D
5.97%
1Q
18.33%
IPO
-85.83%
Name
Hbm Holdings Ltd
Chart & Performance
P/E
6.17
P/S
1.57
EPS
0.03
Div Yield, %
0.00%
Shrs. gr., 5y
-0.67%
Rev. gr., 5y
127.06%
Revenues
90m
+120.13%
Net income
23m
P
CFO
-19m
L-80.87%
Earnings
Mar 26, 2025
Profile
HBM Holdings Limited, a clinical-stage biopharmaceutical company, engages in the discovery and development of differentiated antibody therapeutics in immunology and oncology disease areas. It is developing Batoclimab (HBM9161), a human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor; Tanfanercept (HBM9036) to treat moderate to-severe dry eye disease; HBM7008, a bispecific antibody targeting tumor Associated antigen; and HBM4003, a human anti-CTLA-4 antibody against cytotoxic T-lymphocyte-associated antigen-4. The company is also developing HBM9022 for the treatment of SARS-COV-2; HBM9302 for the treatment of breast and gastric cancers; HBM7020 for the treatment of multiple myeloma; and HBM1007, HBM1029, HBM7015, HBM7008, and HBM1022 for the treatment of solid tumors. It operates in Mainland China, the United States, Europe, and internationally. The company has collaboration on antibody-drug conjugate projects with LegoChem Biosciences Inc. and Duality Biotherapeutics, Inc. HBM Holdings Limited was incorporated in 2016 and is based in Shanghai, the People's Republic of China.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | |
| Income | ||||||
Revenues | 89,502 120.13% | 40,659 843.80% | 4,308 -69.46% | |||
Cost of revenue | 67,675 | 145,353 | 117,565 | |||
Unusual Expense (Income) | ||||||
NOPBT | 21,827 | (104,694) | (113,257) | |||
NOPBT Margin | 24.39% | |||||
Operating Taxes | (81) | 248 | 49 | |||
Tax Rate | ||||||
NOPAT | 21,908 | (104,942) | (113,306) | |||
Net income | 22,797 -116.61% | (137,268) -0.44% | (137,878) -53.50% | |||
Dividends | ||||||
Dividend yield | ||||||
Proceeds from repurchase of equity | (708) | (1,506) | (16,230) | |||
BB yield | 0.05% | 0.07% | 0.29% | |||
| Debt | ||||||
Debt current | 37,434 | 42,406 | 3,391 | |||
Long-term debt | 30,183 | 51,260 | 23,502 | |||
Deferred revenue | 14,079 | 13,860 | 363 | |||
Other long-term liabilities | 1 | |||||
Net debt | (78,855) | (84,396) | (195,254) | |||
| Cash flow | ||||||
Cash from operating activities | (19,122) | (99,964) | (125,609) | |||
CAPEX | (2,397) | (18,438) | (14,202) | |||
Cash from investing activities | 28,087 | 137,590 | (76,903) | |||
Cash from financing activities | (29,143) | 70,575 | 1,589 | |||
FCF | (14,513) | (97,692) | (120,769) | |||
| Balance | ||||||
Cash | 140,725 | 171,705 | 216,304 | |||
Long term investments | 5,747 | 6,357 | 5,843 | |||
Excess cash | 141,997 | 176,029 | 221,932 | |||
Stockholders' equity | (711,644) | (725,590) | (590,707) | |||
Invested Capital | 911,364 | 922,407 | 832,965 | |||
ROIC | 2.39% | |||||
ROCE | 10.82% | |||||
| EV | ||||||
Common stock shares outstanding | 742,530 | 729,435 | 732,377 | |||
Price | 1.92 -31.67% | 2.81 -63.22% | 7.64 -27.24% | |||
Market cap | 1,425,658 -30.45% | 2,049,713 -63.37% | 5,595,363 203.12% | |||
EV | 1,346,444 | 1,964,992 | 5,399,830 | |||
EBITDA | 26,458 | (96,659) | (106,448) | |||
EV/EBITDA | 50.89 | |||||
Interest | 3,872 | 1,987 | 176 | |||
Interest/NOPBT | 17.74% | |||||